help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grüters, A.
Right arrow Articles by Gudermann, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grüters, A.
Right arrow Articles by Gudermann, T.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 5 1431-1436
Copyright © 1998 by The Endocrine Society

Special Articles

Severe Congenital Hyperthyroidism Caused by a Germ-Line neo Mutation in the Extracellular Portion of the Thyrotropin Receptor1

Annette Grüters, Torsten Schöneberg, Heike Biebermann, Heiko Krude, Hans Peter Krohn, Henning Dralle and Thomas Gudermann

Pediatric Endocrinology, Children’s Hospital, Charité-Virchow-Klinikum, Humboldt-Universität zu Berlin (A.G., H.B., H.K.), and the Institute of Pharmacology, Freie Universität (T.S., T.G.), Berlin; Reinhard Nieter Children’s Hospital (H.P.K.), Wilhelmshaven; and the Department of Surgery, University of Halle (H.D.), Halle, Germany

Address all correspondence and requests for reprints to: Dr. Annette Grüters, University Children’s Hospital, Humboldt University, Augustenburger Platz 1, D-13353 Berlin, Germany. E-mail: grueters{at}ukrv.de


   Abstract
Top
 Abstract
Introduction
 Case Report
 Results
 Discussion
 References
 
Gain of function mutations in the TSH receptor (TSHR) have been identified as the molecular basis for congenital and acquired forms of autonomous thyroid function. Herein, we report the molecular characterization of a case of severe congenital hyperthyroidism with a history of hyperthyroidism in the paternal aunt and the paternal grandmother, who were both found to be heterozygous for a mutation (R528H) located in exon 10 of the TSHR gene. Functional expression of the mutant TSHR-R528H in COS-7 cells, however, did not result in constitutive activity of the TSHR. Subsequent analysis of exons 1–9 led to the detection of an additional heterozygous mutation (S281N) in the patient, but not in other family members. Interestingly, the latter mutation is located in the extracellular domain of the TSHR, and functional studies revealed a marked increase in basal cAMP levels when the mutant receptor was expressed in COS-7 cells. To address the question of whether both mutations were present on the same allele, a double mutant TSHR (S281N/R528H) was generated and characterized. These functional studies in conjunction with RT-PCR analysis of thyroid tissue obtained from subtotal thyroidectomy performed at the age of 6 yr revealed that the patient bears two distinct mutations on different alleles: the familial paternal R528H mutation to be regarded as a polymorphism and a de novo mutation (S281N) on the maternal allele accounting for the clinical picture. Thus, the main conclusions to be drawn from this case are 1) a search for mutations in cases of congenital nonautoimmune hyperthyroidism should not remain restricted to exon 10 of the TSHR gene, because germ-line gain of function mutations of the TSH receptor can be located outside of the transmembrane core of the receptor; and 2) this case illustrates the necessity for careful functional characterization of any novel mutation before a causal relationship to hyperthyroidism can be established.


   Introduction
Top
 Abstract
 Introduction
Case Report
 Results
 Discussion
 References
 
CONGENITAL hyperthyroidism is a rare disease that is usually caused by transplacental passage of maternal TSH receptor (TSHR)-stimulating autoantibodies in Graves’ disease (1). Sporadic cases of congenital nonautoimmune hyperthyroidism (2, 3, 4) and a few cases of familial nonautoimmune hyperthyroidism with onset of disease during childhood or even later (5, 6) were found to be caused by mutations within the TSHR gene leading to constitutive activity of the receptor. To date, all germ-line mutations responsible for acquired and congenital forms of nonautoimmune hyperthyroidism were localized in exon 10 encoding the entire transmembrane region of the TSHR (Fig. 1Go). Only very recently has a somatic mutation in a hyperfunctioning thyroid adenoma been identified by an amino acid exchange in the extracellular portion of the TSHR (7).



View larger version (56K):
[in this window]
[in a new window]
  		Figure 1. Location of TSHR mutations found in the family and other patients with hyperthyroidism due to activating germ-line mutations of the TSHR. The receptor protein is presumed to form a closely packed bundle of seven transmembrane domains connected by three extracellular and three intracellular loops. The mutations identified in this study are indicated by enlarged symbols [numbering according to Nagayama et al. (17)]. Gain of function mutations in exon 10 of the human TSHR gene leading to nonautoimmune hyperthyroidism (4–6) are indicated as circles when occurring familially and as squares when occurring sporadically (2–4).

 
In the present study, we examined a girl with nonautoimmune congenital hyperthyroidism and a history of hyperthyroidism of adult onset in the paternal aunt and paternal grandmother. Interestingly, all previously reported cases of congenital nonautoimmune hyperthyroidism had occurred sporadically, probably because the severity of hyperthyroidism had prevented familial transmission. These considerations notwithstanding, we initially hypothesized that congenital hyperthyroidism was caused by a germ-line mutation of the TSHR gene leading to constitutive receptor activity in several family members, and we set out to characterize the molecular TSHR defect in our patient.


   Case Report
Top
 Abstract
 Introduction
 Case Report
Results
 Discussion
 References
 
The female patient was born in the 36th week of gestation with a birth weight of 2520 g (50th percentile) and a length of 49 cm (90th percentile). Both parents were healthy and negative for a history of thyroid disease. However, in three generations, several members of the paternal family developed thyroid disease. In particular, hyperthyroidism had been reported for the paternal grandmother and paternal aunt (Fig. 2Go). The paternal grandmother and paternal aunt had always been negative for TSHR antibodies. Both had low titer antithyroperoxidase antibodies (300 and 1000 U/mL, respectively).



View larger version (28K):
[in this window]
[in a new window]
  		Figure 2. Pedigree of the investigated family.

 
Retrospectively, the parents reported that restlessness, frequent crying, sweating, and diarrhea had been present in the first weeks of life. The persistence of these symptoms led to pediatric consultation after 4 weeks, but the diagnosis of hyperthyroidism was delayed until the age of 4 months. She presented with severe irritability, sweating, diarrhea, tachycardia (180–200/min), an elevated blood pressure amplitude (105/53 mm Hg), and staring eyes without further signs of ophthalmopathy, yet no signs of thyroid enlargement. Free thyroid hormone values were profoundly elevated [free T4 (fT4), 7.5 ng/dL (96.8 pmol/L); free T3 (fT3), 26.6 pg/mL (40.9 pmol/L)]. TSH was suppressed to 0.04 mU/L and showed no increase after TRH administration. Retrospective analysis of the fT4 level in a filter paper specimen obtained on the fifth day of life revealed a concentration of 3.9 ng/dL (50.7 pmol/L), whereas the TSH level had previously been reported as normal (<5 mU/L) by the neonatal screening laboratory. Tests for antithyroid antibodies were negative in the patient as well as in both parents, who had normal thyroid hormone levels (Table 1Go).


View this table:
[in this window]
[in a new window]
  		Table 1. Assessment of thyroid function in the propositus and other family members

 
Although symptoms promptly resolved with thiamazole and propanolol treatment, they reoccurred whenever an attempt was made to reduce the dose of antithyroid drug therapy. After 1 yr, a neurosurgical intervention became necessary because of craniosynostosis. The failure to prevent this complication despite antithyroid drug treatment in conjunction with the observation of immediate relapses of hyperthyroidism after dose reduction led to the decision to perform thyroidectomy at the age of 6 yr. Thereafter, thyroid hormone values remained in the normal range without antithyroid drug treatment, but TSH levels were suppressed.

Methods

Neonatal TSH, serum TSH, serum T4, and serum T3 were measured with an immunofluorometric assay (Delfia, Wallac, Freiburg, Germany) or RIA. Serum fT4, fT3, antithyroperoxidase, antithyroglobulin, and TSHR antibodies were measured by RIA (Dynotest, Brahms Diagnostica, Berlin, Germany).

For mutation analyses, genomic DNA, PCR, single strand conformation polymorphism (SSCP), and sequencing were performed as described previously (8).

Construction of mutant TSHR genes

To characterize functional properties of the novel mutant TSHRs (Fig. 1Go) detected in this study, mutations were created by standard PCR mutagenesis techniques (9) using the human TSHR expression plasmid, TSHR-pcD-PS (8), as a template in which the Bsu36I/BstEII segment had been replaced by a corresponding fragment amplified from genomic DNA. PCR fragments containing the S281N and R528H mutations were digested and used to replace the corresponding KpnI/MscI and MscI/Bsu36I fragments, respectively. The identities of the different constructs and the correctness of all PCR-derived sequences were confirmed by restriction analysis and dideoxy sequencing.

Cell culture, expression, and functional characterization of TSHR constructs

COS-7 cells were grown and transiently transfected as described previously (8).

For inositol phosphate (IP) and cAMP measurements, cells were split into 12-well plates (2 x 105 cells/well) and transfected on the subsequent day. Approximately 24 h after transfection, 2 µCi/mL myo-[3H]inositol (18.6 Ci/mmol; Amersham, Aylesbury, UK) or [3H]adenine (28.8 Ci/mmol; DuPont-New England Nuclear, Brussels, Belgium) were added to the growth medium. After a 20- to 24-h labeling period, IP and cAMP accumulation assays were performed as described previously (10, 11).

For radioligand binding studies, cells were harvested 72 h after transfection, and displacement binding assays were performed with membranes prepared as preivously described (12). Incubations were carried out in a volume of 0.25 mL for 1 h at 22 C in the presence of 40,000 cpm [125I]bovine (b) TSH (54 µCi/µg; Brahms Diagnostica) and bTSH ranging from 0.001–100 mU/mL. Nonspecific binding was defined as binding in the presence of 100 mU/mL bTSH. Membranes and bound ligand were separated from unbound ligand by centrifugation (10,000 x g for 10 min) through a silicon oil layer according to the procedure of McArdle et al. (13). The protein content of samples was determined by the method of Bradford (14). Binding data were analyzed by a nonlinear least squares curve-fitting procedure using the program Ligand (15).

Ribonucleic acid (RNA) preparation and RT-PCR

Tissue obtained from subtotal thyroidectomy was subjected to RT-PCR. About 250 mg thyroid tissue were homogenized with a mortar and pestle under liquid nitrogen. RNA was prepared using the Trizol method (Life Technologies, Eggenstein, Germany). First strand complementary DNA was synthesized by RT (Stratagene, Heidelberg, Germany), using an oligo(deoxythymidine) primer as recommended. Then, a DNA fragment spanning the entire nucleotide sequence of exons 9 and 10 was amplified by PCR with the sense primer 5'-G GAC GTG TCT CAA ACC AG-3' and the antisense primer 5'-GCA GCA GAC GAT GAC GAA GG-3'. The purified PCR product was cloned into the pCR-TOPO vector (Invitrogen, Leek, The Netherlands), and 10 clones were sequenced.


   Results
Top
 Abstract
 Introduction
 Case Report
 Results
Discussion
 References
 
Identification of TSHR mutations

Five DNA fragments encompassing the entire exon 10 of the TSHR of the patient were amplified by PCR. As indicated in Fig. 3BGo, the PCR products representing a 401-bp segment (nucleotide position 1397–1797) showed marked differences in electrophoretic mobility compared with amplification products from her healthy brother or mother (see Fig. 3BGo). Further investigation of all family members available identified the sister, father, paternal aunt, and paternal grandmother as heterozygote carriers of the abnormality in exon 10. Direct sequencing of the segment was performed, and a G to A transition in codon 528 was identified, leading to an R to H exchange. The mutation in exon 10 within one allele led to the loss of a HhaI restriction site in the 401-bp fragment that could now be used to identify this mutation in other family members (see Fig. 3CGo).



View larger version (72K):
[in this window]
[in a new window]
  		Figure 3. Identification of the R528H and S281N mutations in the TSHR gene. A, The pedigree of the investigated family (filled gray symbols, affected family members with a history of hyperthyroidism; the patient is identified by a black circle). Genomic DNA was prepared from blood samples, and five overlapping fragments spanning the entire exon 10 were amplified by PCR. A representative SSCP analysis of PCR products (from nucleotide positions 1397–1797) containing the site of the R528H mutation is shown (B). SSCP analysis was performed according to the method of Biebermann et al. (8). PCR products were digested with HhaI and separated on a 2% agarose gel (C). Only the DNA fragment derived from the wild-type allele was cut by the restriction endonuclease. D displays the SSCP analysis of the exon 9 fragment containing the S281N mutation.

 
Expression and functional characterization of the wild-type and mutant TSHR

To functionally characterize this novel TSHR mutation, we expressed wild-type and mutant TSHRs in COS-7 cells and performed cAMP and IP accumulation as well as [125I]TSH binding assays in parallel. As shown in Fig. 4AGo, COS-7 cells transfected with the R528H mutant displayed lower basal cAMP levels compared with the wild-type TSHR. Maximum increases in cAMP levels after bTSH stimulation (100 mU/mL) were reduced by about 40% in cells expressing TSHR-R528H (Fig. 4AGo and Table 2Go). As functional expression of TSHR R528H could not offer an explanation for the occurrence of severe congenital hyperthyroidism in our patient, we extended sequence and SSCP analyses to exons 1–9 of all family members. As shown in Fig. 3DGo, a heterozygous, abnormally migrating fragment was found in the patient’s exon 9, but not in other family members. Sequence analysis revealed a G to A transition in codon 281, resulting in an S to N exchange. Sequencing of the other TSHR exons revealed no additional mutations in the TSHR gene of the investigated family members.



View larger version (32K):
[in this window]
[in a new window]
  		Figure 4. Comparison of functional properties of the wild-type and mutant TSHRs in cAMP and IP accumulation assays. COS-7 cells were transiently transfected with plasmids encoding wild-type and various mutant TSHRs. Seventy-two hours after transfection, cells were incubated in the absence (open bars) or presence of 100 mU/mL bTSH (close bars), and cAMP (A) and IP (B) accumulation assays were performed as previously described (10, 11). Data are presented as the mean ± SEM of two independent experiments, each performed in triplicate.

 

View this table:
[in this window]
[in a new window]
  		Table 2. Functional characterization of wild-type (wt) and mutant TSHRs

 
Since this study was performed, Duprez et al. (7) identified a constitutively activating mutation in the same codon of exon 9 in an autonomous adenoma. In accordance with this observation, Fig. 4AGo shows that the basal cAMP levels of COS-7 cells transfected with the S281N mutant were significantly elevated. As the TSHR is known to activate the cAMP and phosphoinositide signaling cascades, all TSHR constructs were analyzed in an IP accumulation assay. We demonstrated that the mutant TSHRs were not constitutively active in terms of IP formation. The S281N and R528H mutations did not alter maximal IP levels after stimulation with TSH (see Fig. 4BGo and Table 2Go).

For characterization of ligand binding properties, wild-type and mutant TSHRs were expressed in COS-7 cells, and [125I]TSH displacement studies were performed. No significant differences between the Ki values were observed among the three mutants compared with the wild-type TSHR (Table 2Go). Membrane expression of all mutant TSHRs was reduced to 35–54% of the wild-type receptor expression level (binding capacity, 315 fmol/mg membrane protein; n = 4; Table 2Go).

Furthermore, we constructed a recombinant TSHR containing both mutations. Expression studies revealed similar functional properties of the R528H/S281N mutant and the wild-type receptor (Table 2Go). To unequivocally clarify the allelic localization of both mutations in our patient, we extracted RNA from thyroid tissue that had been collected at the time of thyroidectomy and performed RT-PCR studies. Therefore, PCR fragments spanning the entire exons 9 and 10 were subcloned, and 10 individual clones were sequenced. As previously indicated by functional studies, the patient was found to be a compound heterozygote, i.e. individual clones contained either the R528H or the S281N mutation. Thus, a de novo germ-line mutation (S281N) on the maternal allele was identified as the cause of severe congenital hyperthyroidism in this patient, whereas the paternal R528H mutation identified in several family members affected by thyroid disorders had to be regarded as a polymorphism.


   Discussion
Top
 Abstract
 Introduction
 Case Report
 Results
 Discussion
References
 
In published cases of congenital hyperthyroidism the disease was caused by de novo mutations (M453T, F631L, S505D) only present in the affected infants (2, 3, 4) and not in the other family members. The first descriptions of pedigrees with autosomal dominant traits due to germ-line mutations (S505R, V509A, N650Y, N670S, C672Y) of the TSHR were presented by Vassart and co-workers (5, 6). A clear correlation between genotype and phenotype was difficult to establish because individuals of the same family harboring identical mutations became overtly hyperthyroid either during infancy or later in adulthood (5), but none of the affected individuals presented with congenital hyperthyroidism. One may speculate that the severity of hyperthyroidism in the congenital cases up until now has prevented familial transmission, because there is no overlap between the mutations leading to either severe congenital forms hyperthyroidism or toxic adenomas and the mutations found in familial nonautoimmune hyperthyroidism with an autosomal dominant trait of inheritance.

In the present case of congenital hyperthyroidism, the grandmother’s hyperthyroidism leading to thyroidectomy in adulthood and the aunt’s hyperthyroidism requiring antithyroid drug treatment since adolescence first suggested inheritance with variable onset of disease. The R528H mutation that was identified in these individuals showed no increased constitutive receptor activation in expression experiments. An alignment of the TSHR sequence of the second intracellular loop with corresponding amino acid sequences of other glycoprotein hormone receptors showed that R528 in the TSHR is naturally replaced by the amino acid H at the corresponding position of the receptor for LH. Therefore, the R528H mutation could not account for congenital hyperthyroidism in our patient.

It has been demonstrated that a deletion mutation in the extracellular portion of the TSHR results in constitutive receptor activity (16), and in a recent study, a mutation in exon 9 (S281N) has been found in a thyrotoxic nodule. The identical de novo mutation (S281N) was found in our patient and constitutively activated the Gs/adenylyl cyclase. Thus, we describe the first case of congenital nonautoimmune hyperthyroidism caused by a de novo germ-line mutation (S281N) in the extracellular domain of the TSHR.

The current concept of TSHR activation has to be extended to a possible involvement of the receptor’s ectodomain. As the TSH receptor displays significant constitutive activity even in the unliganded state, it is possible that a negative constraint exerted by the extracellular unliganded domain usually maintains receptor quiescence. A mutation within the extracellular domain disrupting a crucial three-dimensional structure necessary for receptor silencing may then lead to constitutive activity.

In our patient, the decision for thyroidectomy was based on clinical grounds before mutational analysis and in vitro characterization. An early time point for thyroidectomy in patients with persisting nonautoimmune hyperthyroidism regardless of the results of sequencing and in vitro studies appears to be mandatory because three of the published cases remained hyperthyroid despite prolonged antithyroid drug treatment (3, 4) and suffered from irreversible sequelae. Analysis of the TSHR gene may help to justify the decision of thyroidectomy, but it has to be taken into account that the results of in vitro findings cannot be directly transferred to the in vivo situation, which is modulated by genetic and epigenetic factors. However, in any case of novel TSHR mutations, thorough functional characterization has to prove the causal relationship to the clinical picture. In this case, the detection and functional analysis of the additional mutation in exon 9 of the TSHR allowed us to conclude that there is no increased risk of developing hyperthyroidism for the patient’s father and sister.


   Acknowledgments
 
We thank Katrin Huhne for excellent technical assistance. We are grateful to Gilbert Vassart for sharing unpublished results and encouraging the study of this family.


   Footnotes
 
1 This work was supported by the Deutsche Forschungsgemeinschaft, Fonds der Chemischen Industrie, and Sonnenfeld-Stiftung. Back

Received October 31, 1997.

Revised January 13, 1998.

Accepted January 20, 1998.


   References
Top
 Abstract
 Introduction
 Case Report
 Results
 Discussion
 References
 

  1. Zakarija M, McKenzie JM. 1983 Pregnancy-associated changes in the thyroid-stimulating antibody of Graves’ disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab. 57:1036–1040.[Abstract/Free Full Text]
  2. Kopp P, van Sande J, Parma J, et al. 1995 Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med. 332:150–154.[Free Full Text]
  3. De Roux N, Polak M, Couet J, et al. 1996 A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metab. 81:2023–2026.[Abstract]
  4. Schwab KO, Sohlemann P, Gerlich M, et al. 1996 Mutations of the TSH receptor as cause of congenital hyperthyroidism. Exp Clin Endocrinol Diabetes. 104(Suppl 4):124–128.
  5. Duprez L, Parma J, Van Sande J, et al. 1994 Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet. 7:396–401.[CrossRef][Medline]
  6. Tonacchera M, Van Sande J, Cetani F, et al. 1996 Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab. 81:547–554.[Abstract]
  7. Duprez L, Parma J, Costagliola S, et al. 1997 Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain. FEBS Lett. 409:469–474.[CrossRef][Medline]
  8. Biebermann H, Schöneberg T, Krude H, Schultz G, Gudermann T, Grüters A. 1997 Persistent congenital hypothyroidism caused by mutations of the human thyrotropin receptor gene. J Clin Endocrinol Metab. 80:3471–3480.
  9. Higuchi R. 1989 Using PCR to engineer DNA. In: Ehrlich HA, ed. PCR technology. New York: Stockton Press; 61–70.
  10. Schöneberg T, Liu J, Wess J. 1995 Plasma membrane localization and functional rescue of truncated forms of a G protein-coupled receptor. J Biol Chem. 270:18000–18006.[Abstract/Free Full Text]
  11. Schöneberg T, Yun J, Wenkert D, Wess J. 1996 Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide. EMBO J. 15:1283–1291.[Medline]
  12. Dörje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR. 1991 Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 256:727–733.[Abstract/Free Full Text]
  13. McArdle CA, Schomerus E, Groner I, Poch A. 1992 Estradiol regulates gonadotropin-releasing hormone receptor number, growth and inositol phosphate production in {alpha}T3-1 cells. Mol Cell Endocrinol. 87:95–103.[CrossRef][Medline]
  14. Bradford MM. 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 72:248–254.[CrossRef][Medline]
  15. Munson PJ, Rodbard D. 1980 LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 107:220–239.[CrossRef][Medline]
  16. Zhang ML, Sugawa H, Kosugi S, Mori T. 1995 Constitutive activation of the thyrotropin receptor by deletion of a portion of the extracellular domain. Biochem Biophys Res Commun. 211:205–210.[CrossRef][Medline]
  17. Nagayama Y, Kaufman KD, Seto P, Rapoport B. 1989 Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun. 165:1184–1190.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
G. Gelwane, N. de Roux, D. Chevenne, J. C. Carel, and J. Leger
Pituitary-Thyroid Feedback in a Patient with a Sporadic Activating Thyrotropin (TSH) Receptor Mutation: Implication That Thyroid-Secreted Factors Other Than Thyroid Hormones Contribute to Serum TSH Levels
J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2787 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Hebrant, J. Van Sande, P. P. Roger, M. Patey, M. Klein, C. Bournaud, F. Savagner, J. Leclere, J. E. Dumont, W. C. G. van Staveren, et al.
Thyroid Gene Expression in Familial Nonautoimmune Hyperthyroidism Shows Common Characteristics with Hyperfunctioning Autonomous Adenomas
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2602 - 2609.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Agrawal and R. R. Dighe
Critical Involvement of the Hinge Region of the Follicle-stimulating Hormone Receptor in the Activation of the Receptor
J. Biol. Chem., January 30, 2009; 284(5): 2636 - 2647.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. R. H. Buch, H. Biebermann, H. Kalwa, O. Pinkenburg, D. Hager, H. Barth, K. Aktories, A. Breit, and T. Gudermann
G13-dependent Activation of MAPK by Thyrotropin
J. Biol. Chem., July 18, 2008; 283(29): 20330 - 20341.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
P. Nurwakagari, A. Breit, C. Hess, H. Salman-Livny, D. Ben-Menahem, and T. Gudermann
A conformational contribution of the luteinizing hormone-receptor ectodomain to receptor activation
J. Mol. Endocrinol., February 1, 2007; 38(2): 259 - 275.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
S.-C. Ho, S.-S. Goh, I. H C Kee, P. K H Chow, C.-P. Yeo, and D. H C Khoo
Effects of genetic immunization of Swiss outbred mice with human thyroid stimulating hormone receptor cDNA plasmids harboring gain-of-function mutations
J. Mol. Endocrinol., February 1, 2007; 38(2): 277 - 288.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Mueller, G. Kleinau, H. Jaeschke, S. Neumann, G. Krause, and R. Paschke
Significance of Ectodomain Cysteine Boxes 2 and 3 for the Activation Mechanism of the Thyroid-stimulating Hormone Receptor
J. Biol. Chem., October 20, 2006; 281(42): 31638 - 31646.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Jaeschke, S. Neumann, G. Kleinau, S. Mueller, M. Claus, G. Krause, and R. Paschke
An Aromatic Environment in the Vicinity of Serine 281 Is a Structural Requirement for Thyrotropin Receptor Function
Endocrinology, April 1, 2006; 147(4): 1753 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
S G Watson, A D Radford, A Kipar, P Ibarrola, and L Blackwood
Somatic mutations of the thyroid-stimulating hormone receptor gene in feline hyperthyroidism: parallels with human hyperthyroidism
J. Endocrinol., September 1, 2005; 186(3): 523 - 537.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. E. Baum, L. C. Solberg, P. Kopp, N. Ahmadiyeh, G. Churchill, J. S. Takahashi, J. L. Jameson, and E. E. Redei
Quantitative Trait Loci Associated with Elevated Thyroid-Stimulating Hormone in the Wistar-Kyoto Rat
Endocrinology, February 1, 2005; 146(2): 870 - 878.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Sangkuhl, A. Schulz, G. Schultz, and T. Schoneberg
Structural Requirements for Mutational Lutropin/Choriogonadotropin Receptor Activation
J. Biol. Chem., November 27, 2002; 277(49): 47748 - 47755.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Ascoli, F. Fanelli, and D. L. Segaloff
The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective
Endocr. Rev., April 1, 2002; 23(2): 141 - 174.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Richter-Unruh, H. T. Wessels, U. Menken, M. Bergmann, K. Schmittmann-Ohters, J. Schaper, S. Tappeser, and B. P. Hauffa
Male LH-Independent Sexual Precocity in a 3.5-Year-Old Boy Caused by a Somatic Activating Mutation of the LH Receptor in a Leydig Cell Tumor
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1052 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Biebermann, T. Schoneberg, C. Hess, J. Germak, T. Gudermann, and A. Gruters
The First Activating TSH Receptor Mutation in Transmembrane Domain 1 Identified in a Family with Nonautoimmune Hyperthyroidism
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4429 - 4433.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. P. N. Themmen and I. T. Huhtaniemi
Mutations of Gonadotropins and Gonadotropin Receptors: Elucidating the Physiology and Pathophysiology of Pituitary-Gonadal Function
Endocr. Rev., October 1, 2000; 21(5): 551 - 583.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
S. Y. Hsu, M. Kudo, T. Chen, K. Nakabayashi, A. Bhalla, P. J. van der Spek, M. van Duin, and A. J. W. Hsueh
The Three Subfamilies of Leucine-Rich Repeat-Containing G Protein-Coupled Receptors (LGR): Identification of LGR6 and LGR7 and the Signaling Mechanism for LGR7
Mol. Endocrinol., August 1, 2000; 14(8): 1257 - 1271.
[Abstract] [Full Text]

Home page
 NeoReviewsHome page
B. Buckingham
The Hyperthyroid Fetus and Infant
NeoReviews, June 1, 2000; 1(6): e103 - 109.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Hussein, S. Chu, and P. J. Fuller
Comment on Analysis of Mutations in Genes of the Follicle-Stimulating Hormone Receptor in Ovarian Granulosa Cell Tumors
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3852 - 3853.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Nakabayashi, M. Kudo, B. Kobilka, and A. J. W. Hsueh
Activation of the Luteinizing Hormone Receptor Following Substitution of Ser-277 with Selective Hydrophobic Residues in the Ectodomain Hinge Region
J. Biol. Chem., September 22, 2000; 275(39): 30264 - 30271.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Nishi, K. Nakabayashi, B. Kobilka, and A. J. W. Hsueh
The Ectodomain of the Luteinizing Hormone Receptor Interacts with Exoloop 2 to Constrain the Transmembrane Region. STUDIES USING CHIMERIC HUMAN AND FLY RECEPTORS
J. Biol. Chem., February 1, 2002; 277(6): 3958 - 3964.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grüters, A.
Right arrow Articles by Gudermann, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grüters, A.
Right arrow Articles by Gudermann, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals